Browsing "1. Journal Papers" by Author : 4229

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:
  • Sort by:
  • In order:
  • Results/Page
  • Authors/Record:

Showing results 218 to 277 of 432

This table browses all dspace content
Issue DateTitleJournal Title
2004Lack of Correlation Between P-glycoprotein and Chemotherapy Resistance in Nasal NK/T-cell LymphomasLEUKEMIA & LYMPHOMA
2015LAMC2 enhances the metastatic potential of lung adenocarcinomaCELL DEATH AND DIFFERENTIATION
2019Landscape of Actionable Genetic Alterations Profiled from 1,071 Tumor Samples in Korean Cancer Patients Cancer Research and Treatment
2016Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III TrialJOURNAL OF CLINICAL ONCOLOGY
2014Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of HER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTANA- A Randomized, Phase III StudyJOURNAL OF CLINICAL ONCOLOGY
2001Leptomeningeal Carcinomatosis in Solid Tumors ; Clinical Manifestation and Treatment Journal of the Korean Cancer Association (대한암학회지)
2006Long-term Survival after Surgical Resection for Liver Metastasis from Gastric Cancer: Two Case Reports CANCER RESEARCH AND TREATMENT
2021MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma FUTURE ONCOLOGY
2019Maintenance avelumab versus continuation of first-line chemotherapy in gastric cancer: JAVELIN Gastric 100 study design FUTURE ONCOLOGY
2022Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort AESMO OPEN
2018Marked Loss of Muscle, Visceral Fat, or Subcutaneous Fat After Gastrectomy Predicts Poor Survival in Advanced Gastric Cancer: Single-Center Study from the CLASSIC TrialANNALS OF SURGICAL ONCOLOGY
2013Mechanism of enhancement of radiation-induced cytotoxicity by sorafenib in colorectal cancer JOURNAL OF RADIATION RESEARCH
1998Menstrual state should be considered in determining sero-positivity of soluble angiogenic factors in breast cancer.INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
2019Mesothelin Expression Is a Predictive Factor for Peritoneal Recurrence in Curatively Resected Stage III Gastric CancerONCOLOGIST
2018MET in gastric cancer with liver metastasis: The relationship between MET amplification and Met overexpression in primary stomach tumors and liver metastasis.JOURNAL OF SURGICAL ONCOLOGY
2012Methylation status of lamin A/C in gastric cancer cell linesHEPATO-GASTROENTEROLOGY
2011MMP-2 as a putative biomarker for carcinomatosis in gastric cancerHEPATO-GASTROENTEROLOGY
2004MN/CA9 촉진자를 가진 replication-competent 아데노바이러스를 이용한 신세포암에 대한 종양 특이적 유전자요법 KOREAN JOURNAL OF UROLOGY
2008Mobilized CD34+ cells as a biomarker candidate for the efficacy of combined maximal tolerance dose and continuous infusional chemotherapy and G-CSF surge in gastric cancerCANCER LETTERS
1999Modulation of biological phenotypes for tumor growth and metastasis by target-specific biological inhibitors in gastric cancerInternational Journal of Molecular Medicine
2017Modulation of HAT activity by the BRCA2 N372H variation is a novel mechanism of paclitaxel resistance in breast cancer cell linesBIOCHEMICAL PHARMACOLOGY
2007Molecular basis of the differences between normal and tumor tissues of gastric cancerBIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
2021Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death-Ligand 1 Blockade ResponsesHEPATOLOGY
2021Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma ANNALS OF ONCOLOGY
2023Monitoring the Outcomes of Systemic Chemotherapy Including Immune Checkpoint Inhibitor for HER2-Positive Metastatic Gastric Cancer by Liquid Biopsy YONSEI MEDICAL JOURNAL
2001Monthly 5-days 5-fluorouracil and low-dose leucovorin for adjuvant chemotherapy in colon cancerCANCER LETTERS
2022MOUNTAINEER-02: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+gastric or gastroesophageal junction adenocarcinoma-Trial in progressJOURNAL OF CLINICAL ONCOLOGY
2007Multi-institutional phase II study of S-1 monotherapy in advanced gastric cancer with pharmacokinetic and pharmacogenomic evaluations ONCOLOGIST
2022Multicenter phase Ib/II study of second-line trastuzumab, ramucirumab, and paclitaxel in patients with HER2-positive advanced gastric or gastroesophageal junction cancer: Updated HER-RAM study with biomarker analysisJOURNAL OF CLINICAL ONCOLOGY
2008Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancerBREAST CANCER RESEARCH AND TREATMENT
2005Neoadjuvant chemotherapy with infusional 5-fluorouracil, adriamycin and cyclophosphamide (iFAC) in locally advanced breast cancer: an early response predicts good prognosis ANNALS OF ONCOLOGY
2016Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus ONCOTARGET
2017Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trialLANCET
2021Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab GASTRIC CANCER
2022Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trialLANCET ONCOLOGY
2007Novel and simple transformation algorithm for combining microarray data sets BMC BIOINFORMATICS
2008Novel biomarker candidates for gastric cancerONCOLOGY REPORTS
2023Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer SCIENTIFIC REPORTS
2009Oncogenic pathway combinations predict clinical prognosis in gastric cancer PLOS GENETICS
2024Open-Label, Multicenter, Randomized, Biomarker-Integrated Umbrella Trial for Second-Line Treatment of Advanced Gastric Cancer: K-Umbrella Gastric Cancer StudyJOURNAL OF CLINICAL ONCOLOGY
2020Osimertinib, an Irreversible Next-Generation EGFR Tyrosine Kinase Inhibitor, Exerts Antitumor Activity in Various Preclinical NSCLC Models Harboring the Uncommon EGFR Mutations G719X or L861Q or S768IMOLECULAR CANCER THERAPEUTICS
2023Outcomes of an Acute Palliative Care Unit at a Comprehensive Cancer Center in Korea PALLIATIVE MEDICINE REPORTS
2010Outcomes of multiple salvage chemotherapy for advanced gastric cancer: implications for clinical practice and trial designCANCER CHEMOTHERAPY AND PHARMACOLOGY
1996Overexpression of c-ErbB-2 Protein in Gastric Cancer by Immunohistochemical StainONCOLOGY
2012Overexpression of class III beta tubulin and amplified HER2 gene predict good response to paclitaxel and trastuzumab therapy PLOS ONE
1996P-glycoprotein as an intermediate end point of drug resistance to neoadjuvant chemotherapy in locally advanced gastric cancer YONSEI MEDICAL JOURNAL
1997P-glycoprotein: The intermediate end point of drug response to induction chemotherapy in locally advanced breast cancerBREAST CANCER RESEARCH AND TREATMENT
2021p16 methylation is a potential predictive marker for abemaciclib sensitivity in gastric cancerBIOCHEMICAL PHARMACOLOGY
1998p53 유전자 변형이 발생한 위암세포주에서 유전자이상 교정에 의한 항암제 감수성 변화 Journal of the Korean Cancer Association (대한암학회지)
2010Paclitaxel combined with ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer: activity independence of prior docetaxel resistanceCANCER CHEMOTHERAPY AND PHARMACOLOGY
2022PD-L1 expression and overall survival in Asian and western patients with gastric cancerFUTURE ONCOLOGY
2020Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 StudiesJOURNAL OF THORACIC ONCOLOGY
2019Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study Gastric Cancer
2016Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trialLANCET ONCOLOGY
2018Pembrolizumab in Asia-Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE-012 CANCER SCIENCE
2023Pembrolizumab or pembrolizumab plus chemotherapy versus standard of care chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma: Asian subgroup analysis of KEYNOTE-062 JAPANESE JOURNAL OF CLINICAL ONCOLOGY
2023Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trialLANCET
2018Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trialLANCET
2022Pembrolizumab with or without chemotherapy versus chemotherapy alone for patients with PD-L1-positive advanced gastric or gastroesophageal junction adenocarcinoma: Update from the phase 3 KEYNOTE-062 trialJOURNAL OF CLINICAL ONCOLOGY
2008Pemetrexed and cisplatin in patients with advanced gastric cancer: a Korean cancer study group multicenter phase II study.CANCER CHEMOTHERAPY AND PHARMACOLOGY

Browse

Links